Toxic Exposures Clinical Trial Award
ID: 355156Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355156
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 (FY24) Toxic Exposures Clinical Trial Award (CTA) to support clinical trials focused on military-related toxic exposures. This funding opportunity aims to facilitate research that addresses the prevention, diagnosis, treatment, and underlying mechanisms of health issues stemming from such exposures, with applicants required to align their proposals with at least one FY24 Toxic Exposures Research Program (TERP) Goal and Topic Area. The initiative is crucial for advancing understanding and management of health consequences related to military service, with a total funding pool of $30 million available, including direct costs capped at $1.5 million for single Principal Investigator (PI) projects and $2.5 million for partnering PI applications. Key deadlines include a pre-application due by August 13, 2024, and a full application by November 7, 2024; interested parties can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524TERPCTA-GG.pdf
    The Department of Defense (DOD) is offering the Fiscal Year 2024 (FY24) Toxic Exposures Clinical Trial Award (CTA) through the Toxic Exposures Research Program (TERP) to support research addressing military-related toxic exposures. This funding opportunity is aimed at clinical trials that will investigate prevention, diagnosis, treatment, and the underlying mechanisms of health issues caused by such exposures. Applicants must align their proposals with at least one FY24 TERP Program Goal and Topic Area, which include elucidating toxic exposure mechanisms and developing therapeutics. Key deadlines include a pre-application by August 13, 2024, and a full application by November 7, 2024. The total funding available is $30 million, with direct costs limited to $1.5 million for single PI projects and $2.5 million for partnering PI applications. Eligible applicants include both extramural and intramural organizations, and the application process involves a two-step submission through the Electronic Biomedical Research Application Portal (eBRAP) and Grants.gov. Proposals emphasizing collaborative efforts with the Department of Veterans Affairs and focusing on military health outcomes are encouraged. The initiative underscores a commitment to understanding and addressing health consequences related to military service exposures.
    Similar Opportunities
    DOD Glioblastoma, Transformative Consortium Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Glioblastoma Transformative Consortium Award, aimed at advancing research to improve outcomes for glioblastoma patients. This grant seeks proposals for innovative, multidisciplinary projects that collectively address a central hypothesis, requiring collaboration among at least four distinct projects and the inclusion of a consumer advocate. With an estimated total program funding of $9 million, the application process includes a pre-application deadline of December 23, 2024, and a full application deadline of January 13, 2025. Interested applicants can reach the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Active
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
    Department of Army Energetics Basic Research Center (EBRC) Fiscal Year 2025
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army, through the Materiel Command, is offering a funding opportunity for the Energetics Basic Research Center (EBRC) for Fiscal Year 2025, aimed at advancing research in energetic materials (EM) critical to U.S. national security. This initiative invites eligible applicants, including universities, nonprofit organizations, state and local governments, and for-profit entities, to submit white papers and proposals that focus on innovative research in EMs, particularly in areas such as novel materials, microstructure influence, and advanced diagnostics. The program is designed to enhance the Army's capabilities in developing new materials and technologies that improve weapon systems' performance and effectiveness, with a total funding ceiling of $1 million anticipated for up to six awards ranging from $60,000 to $250,000 per year. Interested parties should submit white papers by January 6, 2025, and proposals by invitation by April 7, 2025; for further inquiries, contact Schon Zwakman at schon.m.zwakman.civ@army.mil or by phone at 919-541-4722.
    Funding Opportunity Title:Deployed Warfighter Protection (DWFP) Program for the Protection of Deployed Military Personnel from Threats Posed by Arthropod Disease Vectors
    Active
    Department of Defense
    The Department of Defense is offering a funding opportunity through the Fiscal Year 2025 Deployed Warfighter Protection (DWFP) Program, aimed at safeguarding military personnel from threats posed by arthropod disease vectors. The program seeks innovative research proposals focused on developing new insecticides, personal protection technologies, and improved vector control strategies, with applications required to address specific research areas such as bite prevention, vector control, and diagnostics. This initiative is crucial for enhancing health protection in military operations and has a total estimated funding of $5 million, with individual awards capped at $975,000 over three years. Interested applicants must submit a pre-application by October 4, 2024, and a full application by January 28, 2025; for further inquiries, contact Scott I. Hoffman at scott.i.hoffman2.civ@army.mil or call 1-520-671-1470.
    NFRP Outreach and Invitation for Response
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    Tactical Behaviors for Autonomous Maneuver
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Notice of Intent to Publish a Funding Opportunity Announcement for CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Countermeasures Against Chemical Threats (CounterACT) initiative, focusing on the early-stage development of therapeutics to address health impacts from toxic chemical exposure. This funding opportunity aims to foster collaborations and innovative projects that can effectively mitigate adverse health effects, with an emphasis on the UG3/UH3 activity code for phased development. The NOFO is anticipated to be released in early 2025, with applications due by October 2025, and awards expected to be made by June 2026, marking a significant investment in public health safety. Interested applicants should prepare to align their proposals with the outlined objectives and timelines.